Clinical Trials Logo

Neisseria Meningitidis clinical trials

View clinical trials related to Neisseria Meningitidis.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT03419533 Completed - Clinical trials for Neisseria Meningitidis

Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers

B Part Of It
Start date: February 1, 2018
Phase:
Study type: Observational

This is an observational cross sectional study to evaluate the impact of a 4CMenB vaccination program on oropharyngeal N. meningitidis carriage in vaccinated and unvaccinated school leavers.

NCT ID: NCT02398396 Completed - Clinical trials for Meningococcal Infections

Investigating Meningococcal Vaccines in Adults

Start date: April 2015
Phase: N/A
Study type: Interventional

This study will be an open label, exploratory immunogenicity study conducted by the Oxford Vaccine Group, University of Oxford. This study will investigate the breadth of protective activity of serum anti-FHbp antibody responses of adults immunized with 4CMenB (Bexsero®) vaccine as well as investigating the nature of the B-cell and T-cell responses induced by vaccination. The investigators aim to enroll 15 to 20 healthy adults aged 18 to 60, who will be immunized with two doses of 4CMenB (Bexsero®) two months apart according to the licensed schedule. Blood samples will be obtained at baseline and after each dose of vaccine.

NCT ID: NCT01978093 Completed - Clinical trials for Haemophilus Influenzae Type b

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

Start date: February 1, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' Hib-MenCY-TT (MenHibrix®) vaccine co-administered with Rotarix, Prevnar 13 and Havrix as compared to PedvaxHIB co-administered with Rotarix, Prevnar 13 and Havrix in infants and toddlers.

NCT ID: NCT01839188 Completed - Clinical trials for Bacterial Infections

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Start date: May 1, 2013
Phase: Phase 3
Study type: Interventional

To evaluate the immune response and the safety of a primary series schedule that includes V419 (PR5I) at 2 and 6 months of age and Pediacel at 4 months of age Primary objectives - To demonstrate that the mixed schedule induces acceptable responses for Hepatitis B (HB) one month after completion of the mixed schedule - To demonstrate that the mixed schedule induces acceptable responses for Haemophilus influenzae type b (Hib) one month after completion of the mixed schedule Secondary objectives - To describe the antibody response to all PR5I antigens one month after completion of the mixed schedule - To describe the antibody response to meningococcal serogroup C (MCC) conjugate vaccine one month after the second dose of MenC vaccine - To describe the safety profile after each dose of study vaccines administered

NCT ID: NCT01839175 Completed - Clinical trials for Bacterial Infections

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Start date: April 2013
Phase: Phase 3
Study type: Interventional

Primary Series Primary objectives - To demonstrate that the concomitant administration of the hexavalent vaccine with a meningococcal serogroup C conjugate vaccine is non inferior to the administration of the hexavalent vaccine without a MenC vaccine concomitantly in term of seroprotection rate for hepatitis B one month after the third dose of the hexavalent vaccine - To demonstrate that the concomitant administration of a MenC vaccine with the hexavalent vaccine induces an acceptable response for MenC in term of seroprotection rate (SPR) one month after the second dose of MenC Booster Primary objectives - To describe the immunogenicity of a booster dose of the hexavalent vaccine and of a meningococcal group ACWY conjugate (MenACWY) vaccine either co-administered at 12 months of age or given separately.

NCT ID: NCT01730391 Completed - Clinical trials for Neisseria Meningitidis

Neisseria Meningitidis Burden of Disease Study

Start date: January 2013
Phase: N/A
Study type: Observational

This study aims to provide an estimate of the proportion of suspected cases of bacterial meningitis that are due to N. meningitidis and the serogroup responsible in The Philippines and Vietnam.

NCT ID: NCT01621945 Completed - Clinical trials for Neisseria Meningitidis

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)

Exten Effivac
Start date: April 2012
Phase: Phase 3
Study type: Observational

The main objective of the study is to estimate the proportion of children, born between the 06/04/2004 and the 17/004/2008, living around Neufchatel en Bray, vaccinated by MenBVac, with a serum bactericidal activity against B:14,P1-7,16 clone related to a protection (>= 4), before the fourth dose of MenBvac and after: 6 weeks and one year after the fourth dose.

NCT ID: NCT01553279 Completed - Clinical trials for Bacterial Infections

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

Start date: March 30, 2012
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the immunogenicity and safety of concomitant administration of V419 (PR51) with 2 types of meningococcal serogroup C conjugate (MCC) vaccines to healthy infants at 3 and 4 months of age in terms of antibody seroprotection rate (SPR) to MCC. Participants also received a Haemophilus influenza type B (Hib)-MCC vaccination at 12 months of age. It was hypothesized that the SPR to MCC at 1 month post-dose 2 of either tetanus toxoid conjugated Meningo C (MCC-TT) or CRM197 conjugated Meningo C (MCC-CRM) vaccines would be acceptable when administered concomitantly with V419.

NCT ID: NCT01218451 Completed - Clinical trials for Neisseria Meningitidis

NeisVac-C Single Prime Study in Infants

Start date: September 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the feasibility of a single priming dose of NeisVac-C in infants (at either 4 or 6 months of age), as determined by immune response.

NCT ID: NCT01090453 Completed - Hepatitis B Clinical Trials

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

Start date: May 17, 2010
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083 vaccine co-administered with Prevenar 13® at 2, 4 and 12 months of age and with Rotarix™ at 2 and 4 months of age.